---
title: "Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference  | ATHE Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301390801.md"
description: "Alterity Therapeutics (NASDAQ: ATHE) announced that CEO David Stamler will present at the Canaccord Genuity Drug and Device Conference on October 12, 2026. The presentation includes a corporate overview and investor roundtable discussions. Alterity is a biotechnology company developing disease-modifying therapies for neurodegenerative diseases like Multiple System Atrophy."
datetime: "2026-10-09T03:05:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301390801.md)
  - [en](https://longbridge.com/en/news/301390801.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301390801.md)
generator: "portal-rs"
---

# Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference  | ATHE Stock News

Alterity Therapeutics (NASDAQ: ATHE) will present at the Canaccord Genuity Drug and Device Conference on October 12, 2026.

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will present at the Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026 at 3:50 p.m. AEST in Australia.

At the conference, Dr. Stamler will deliver a corporate presentation and will also host roundtable discussions with investors.

**About Alterity Therapeutics Limited** 

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.

**Authorisation & Additional information**  
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

**Contacts:**

**Investors**  
Elyse Shapiro  
ir@alteritytx.com

Remy Bernarda  
Investor Relations Advisory Solutions  
ir@alteritytx.com  
+1 (415) 203-6386

**Media**  
Melissa Tempra  
NWR Communications  
melissa@nwrcommunications.com.au

Casey McDonald  
Tiberend Strategic Advisors, Inc.  
cmcdonald@tiberend.com  
+1 (646) 577-8520

### Related Stocks

- [ATHE.US](https://longbridge.com/en/quote/ATHE.US.md)
- [ATH.AU](https://longbridge.com/en/quote/ATH.AU.md)

## Related News & Research

- [Alterity Therapeutics Issues 8.4 Million Shares Under Underwriting Deal](https://longbridge.com/en/news/298249430.md)
- [Insider Move at Biotech Firm Sparks Fresh Investor Interest](https://longbridge.com/en/news/298398581.md)
- [Alterity Therapeutics Seeks Quotation for New ASX Shares](https://longbridge.com/en/news/299120002.md)
- [Alterity Therapeutics issues 8,400,000 shares tied to exercised options at A$ 0.5 each](https://longbridge.com/en/news/298298137.md)
- [Alterity Therapeutics issues shares from exercise of listed options at A$0.5 each](https://longbridge.com/en/news/297504784.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**